Moll, Matthew
Hobbs, Brian D.
Menon, Aravind
Ghosh, Auyon J.
Putman, Rachel K.
Hino, Takuya
Hata, Akinori
Silverman, Edwin K.
Quackenbush, John
Castaldi, Peter J.
Hersh, Craig P.
McGeachie, Michael J.
Sin, Don D.
Tal-Singer, Ruth
Nishino, Mizuki
Hatabu, Hiroto
Hunninghake, Gary M.
Cho, Michael H.
Funding for this research was provided by:
National Heart, Lung, and Blood Institute
National Institutes of Health
Canadian Institutes of Health Research
COPD Foundation
Article History
Received: 31 January 2022
Accepted: 3 June 2022
First Online: 17 June 2022
Declarations
:
: All COPDGene and ECLIPSE study participants provided written informed consent. Each study center obtained institutional review board (IRB) approval (Mass General Brigham IRB protocol 2007P000554).
: Not applicable.
: MM received grant support from Bayer. EKS received grant support from GlaxoSmithKline and Bayer. CPH reports grant support from Boehringer-Ingelheim, Novartis, Bayer and Vertex, outside of this study. MN has received research grants to the institution from AstraZeneca, Daiichi Sankyo, Canon Medical Systems, and has served as a consultant to AstraZeneca, and Daiichi Sankyo. PJC has received grant support from GlaxoSmithKline and Bayer and consulting fees from GlaxoSmithKline and Novartis. RTS was employed by GlaxoSmithKline until 2019 and is a shareholder of GlaxoSmithKline stock; RTS received consulting fees from Immunomet, ENA Respiratory, Teva, and Vocalis Health; she is currently a Board Member of ENA Respiratory on behalf of the COPD Foundation. JQ is on the scientific advisory boards of Caris Life Sciences and Renalytix. HH received grants from Canon Medical Systems Inc and Konica-Minolta Inc. and served as consultant for Mitsubishi Chemical Co and Canon Medical Systems Inc outside of this study. GMH has performed consulting work for Boehringer-Ingelheim, and the Gerson Lehrman Group within the last 3 years. MHC has received grant support from GlaxoSmithKline and Bayer, consulting fees from Genentech and AstraZeneca, and speaking fees from Illumina.